ADCETRIS (brentuximab vedotin), monoclonal antibody

Substantial clinical benefit in the treatment of CD30+ Hodgkin’s lymphoma with increased risk of relapse or progression following autologous stem cell transplant and minor clinical added value in the management of this disease

• ADCETRIS has Marketing Authorisation in the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).
• Its efficacy has been demonstrated compared with placebo in terms of progression-free survival.
• A gain in overall survival has not been demonstrated to date, and so the benefit of this preventive strategy for post-ASCT recurrence cannot be determined compared with the treatment of the relapse with brentuximab vedotin.
• Serious adverse events may occur during treatment with brentuximab vedotin.